Daratumumab - Wikipedia
Daratumumab, sold under the brand name Darzalex among others, is an anti-cancer monoclonal antibody medication. It binds to CD38, [7] which is overexpressed in multiple myeloma cells. [8] .
Daratumumab (intravenous route) - Mayo Clinic
2024年1月31日 · Daratumumab can temporarily lower the number of white blood cells in your blood, increasing the chance of getting an infection. It can also lower the number of platelets, which are necessary for proper blood clotting.
Daratumumab - NCI - National Cancer Institute
This page contains brief information about daratumumab and a collection of links to more information about the use of this drug, research results, and ongoing clinical trials.
Daratumumab Information from Drugs.com
2024年10月14日 · Daratumumab ( Darzalex) is a treatment for multiple myeloma to help slow or stop cancer from progressing. Includes Daratumumab side effects, uses, dosage regimes, and more.
Daratumumab (DARZALEX) | FDA
The recommended dose of daratumumab is 16 mg/kg intravenously (calculated on actual body weight). FDA granted daratumumab breakthrough therapy and orphan drug designation, as well as...
Darzalex (daratumumab) - Uses, Side Effects, and More - WebMD
2024年8月20日 · Darzalex (daratumumab) is commonly used for treating multiple myeloma, which is a type of blood cancer. Darzalex can be used in certain people who have or have not …
Daratumumab, Bortezomib, Lenalidomide, and Dexamethasone …
2023年12月12日 · Daratumumab is a human IgGκ monoclonal antibody targeting CD38 with direct on-tumor 5-8 and immunomodulatory 9-11 mechanisms of action.
Daratumumab: a first-in-class CD38 monoclonal antibody for …
Daratumumab is a human monoclonal antibody that targets CD38, a cell surface protein that is overexpressed on multiple myeloma (MM) cells. Preclinical studies have shown that daratumumab induces MM cell death through several mechanisms, including ...
Evaluating Daratumumab in the Treatment of Multiple Myeloma: …
Daratumumab is a human monoclonal antibody that targets a unique epitope on the CD38 glycoprotein. Daratumumab induces cell death through various Fc-dependent immune effector mechanisms.
Darzalex Faspro, Sarclisa Approvals for Multiple Myeloma
2025年1月7日 · Daratumumab approval for transplant-eligible patients. FDA based its new approval of daratumumab for transplant-eligible patients on the results of a large clinical trial called PERSEUS, which was funded by the European Myeloma Network and Janssen, the manufacturer of daratumumab.